The Swiss firm's ScaiVision software identifies disease-linked cells using AI, data visualization, and automation of hypothesis testing.
The study identified one genetic and three protein-based biomarkers associated with outcome in Pseudomonas bloodstream infections.
The multi-analyte assay could screen for cancers that currently lack early-stage detection methods, including ovarian, liver, stomach, pancreatic, and esophageal cancers.
The German firm grew revenues to €5.3 million for the first nine months of the year from €976,000 a year ago, but its net loss expanded 48 percent year over year.
Johns Hopkins researchers added protein analysis to circulating tumor DNA testing to better detect early-stage pancreatic cancer.
The partners aim to enable the early prediction of clinical efficacy of Alligator's pipeline candidates by analyzing potential systemic biomarkers.
The company plans to develop tests for prostate cancer risk assessment, prostate cancer screening, and breast cancer screening.
The Medicare contractor proposed coverage for several cancer assays, but would not cover molecular respiratory virus assays or a test for inflammatory bowel disease.
New data from Peregrine Pharmaceuticals, along with other recent research, suggests that surface proteins can be used to isolate cancer-specific exosomes to detect the presence of a tumor.
Researchers showed it could differentiate pancreatic cancer cases from controls with high sensitivity, and believe it could work similarly for other cancers or in infectious disease.
The New York Times Magazine examines gender discrimination at the Salk Institute.
Science reports that MD Anderson Cancer Center has dismissed three researchers over foreign tie concerns.
A second death in gene therapy trial for type 1 spinal muscular atrophy is under investigation, according to Reuters.
In PLOS this week: antibiotic resistance patterns in Escherichia coli, a dozen genetic loci tied to varicose vein risk, and more.